Inactivation of TGF beta receptors in stem cells drives cutaneous squamous cell carcinoma by Cammareri, P et al.
1 
 
Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell 1 
carcinoma 2 
 3 
Patrizia Cammareri1,13, Aidan M Rose2,13, David F Vincent1,13, Jun Wang3, Ai Nagano3, Silvana 4 
Libertini1, Rachel A Ridgway1, Dimitris Athineos1, Philip J Coates4, Angela McHugh2, Celine 5 
Pourreyron2, Jasbani H S Dayal2, Jonas Larsson5, Simone Weidlich6, Lindsay C Spender2, 6 
Gopal P Sapkota6, Karin J Purdie7,  Charlotte M Proby2, Catherine A Harwood7, Irene M 7 
Leigh2,7, Hans Clevers8, Nick Barker9, Stefan Karlsson5, Catrin Pritchard10, Richard Marais11, 8 
Claude Chelala3, Andrew P South2,12, Owen J Sansom1* and Gareth J Inman2*. 9 
 10 
1 Cancer Research UK Beatson Institute, Institute of Cancer Sciences, Glasgow University, 11 
Glasgow, G61 1BD, UK 12 
2Division of Cancer Research, School of Medicine, University of Dundee, Dundee, DD1 9SY, 13 
UK 14 
3Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, 15 
London, E1 4NS, UK 16 
4Tayside Tissue Bank, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK 17 
5Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund 18 
University, Lund, 221 00, Sweden 19 
6MRC Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee, 20 
DD1 5EH, UK 21 
7Centre for Cutaneous Research, Barts and the London School of Medicine and Dentistry, 22 
Queen Mary University of London, E1 2AT, London, UK 23 
2 
 
8Hubrecht Institute, Utrecht, 3584 CT, The Netherlands 24 
9Institute of Medical Biology, Immunos, 138648, Singapore 25 
10Department of Biochemistry, University of Leicester, Leicester, LE1 9HN, UK 26 
11The Paterson Institute for Cancer Research, Manchester, M20 4BX, UK 27 
12Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, 28 
Philadelphia, PA 19107, USA. 29 
 30 
 31 
13These authors contributed equally to this work. 32 
*Correspondence: Gareth J Inman, Jacqui Wood Cancer Centre, Ninewells Hospital and 33 
Medical School, Dundee, DD1 9SY. g.j.inman@dundee.ac.uk; Owen J Sansom, Cancer 34 
Research UK Beatson Institute, Garscube Estate, Glasgow, G61 1BD. 35 
o.sansom@beatson.gla.ac.uk 36 





Melanoma patients treated with oncogenic BRAF inhibitors can develop cutaneous 40 
squamous cell carcinoma (cSCC) within weeks of treatment, driven by paradoxical 41 
RAS/RAF/MAPK pathway activation. Here, we identify frequent TGFBR1 and TGFBR2 42 
mutations in human vemurafenib-induced skin lesions and in sporadic cSCC. Functional 43 
analysis reveals these mutations ablate canonical TGFβ Smad signaling which is localised 44 
to bulge stem cells in both normal human and murine skin. MAPK pathway 45 
hyperactivation (through BrafV600E or KrasG12D knockin) and TGFβ signaling ablation 46 
(through Tgfbr1 deletion) in LGR5+ve stem cells enables rapid cSCC development in the 47 
mouse. Mutation of Tp53 (which is commonly mutated in sporadic cSCC) coupled with 48 
Tgfbr1 deletion in LGR5+ve cells also results in cSCC development. These findings indicate 49 
that LGR5+ve stem cells can act as cells of origin for cSCC and that RAS/RAF/MAPK pathway 50 
hyperactivation or Tp53 mutation, coupled with loss of TGFβ signaling, are driving events 51 




Introduction  56 
The development  of epithelial tumors is generally accepted to take place over several years, 57 
involving the accumulation of mutations which drive tumor progression1. However, some 58 
tumors contain a relatively low mutation burden2 and develop rapidly, without progression 59 
from benign intermediary stages, suggesting a potential stem cell origin3. Data from murine 60 
model systems illustrate a tumor’s ability to form from both stem and differentiated cells. 61 
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Within intestinal epithelium, loss of Apc in the LGR5+ve stem cell compartment leads to 62 
adenoma, whilst tumors rarely form from differentiated cells4. Conversely, we have shown 63 
that targeting Kras, in addition to Apc, can de-differentiate intestinal villi and permit tumor 64 
formation5. Thus, the tumor cell of origin remains unclear, as does the standard model of 65 
progression from benign tumor to malignant carcinoma.  66 
 67 
Discord with the progression model is exemplified in the skin, which carries a high mutation 68 
burden6. Asymptomatic normal skin carries frequent mutations in TP537,8 and NOTCH6,8. 69 
Classic chemical carcinogenesis DMBA/TPA experiments demonstrate Hras mutations can lie 70 
dormant in the skin (without the addition of TPA), at no obvious consequence to the tissue9. 71 
Indeed even when Ras mutation is targeted to stem cell compartments (e.g LRIG1+ve cells or 72 
bulge stem cells10,11), this does not lead to cancer unless there is a disruption of tissue 73 
homeostasis through wounding. These findings support the hypothesis that homeostasis 74 
within stem cell compartments plays an important tumor suppressive role in highly 75 
organised structures such as skin.  76 
We reasoned that, in the absence of wounding, mutations in other oncogenic/tumour 77 
suppressor genes might facilitate rapid skin tumorigenesis. Using targeted sequence analysis 78 
and whole exome sequencing (WES), we identify frequent mutation in both TGFβ type 1 79 
receptor (TGFBR1) and TGFβ type 2 receptor (TGFBR2) genes in human primary cSCC 80 
samples. IntOgen mutation analysis reveals TGFβ signaling as a pathway significantly altered 81 
by mutation and functional analysis of several TGFβ receptor mutants indicates that many 82 
of these mutations result in loss of function. Pathway activation studies reveal highly 83 
localised TGFβ signaling in both normal human and mouse hair follicle bulge stem cells. In 84 
murine skin, targeted activation of the RAS/RAF/MAPK pathway, coupled with deletion of 85 
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Tgfbr1 in LGR5+ve stem cells promotes rapid development of cSCC which, in the absence of 86 
wounding, may mimic the kinetics of tumor induction in vemurafenib-induced cSCC. 87 
Combined Tp53 mutation/inactivation coupled with Tgfbr1 loss in LGR5+ve stem cells also 88 




TGFBR1 and TGFBR2 are frequently mutated in human cSCC 93 
Cutaneous squamo-proliferative lesions (including keratoacanthomas and cSCC) arise in a 94 
significant proportion of patients treated with the type I RAF inhibitor vemurafenib. Such 95 
lesions develop within a few weeks of treatment12,13. Targeted sequencing has revealed that 96 
these lesions contain a high frequency of activating mutations in HRAS6,12,13. Cutaneous 97 
lesions isolated from patients treated with sorafenib (the “pan-RAF” inhibitor) also harbour 98 
mutations in HRAS, TP53 and TGFBR114. Employing targeted deep sequencing of 39 squamo-99 
proliferative lesions from 7 patients (including cSCC and actinic keratosis (AK); 100 
Supplementary Table 1) treated with vemurafenib (using a percentage variance criterion of 101 
>10%) we identified frequent coding mutations in both TGFBR1 (8/39, 21% of samples) and 102 
TGFBR2 (5/39, 13% of samples) revealing mutation of TGFβ receptors in 28% of lesions (Fig. 103 
1a, Supplementary Data 1). These mutational events were only surpassed in frequency by 104 
mutations in NOTCH1/NOTCH2 (56%) and activating mutations of HRAS (38%). TP53 105 
mutations arose in 26% of lesions6 (Fig. 1a, Supplementary Data  2). In contrast to NOTCH, 106 
(using our mutational call cut off, see  Methods) we did not detect any mutations in TGFβ 107 
receptors or HRAS in the normal or perilesional skin samples (n=6 from 4 patients, 3 of 108 
which had lesions containing TGFβ receptor mutations). These findings imply that a 109 
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combination of potential mutational inactivation of TGFβ signaling and activation of HRAS 110 
may be important driving events in vemurafenib-induced skin lesions and skin 111 
tumorigenesis. 112 
 113 
We next sought to investigate whether loss of TGFβ signaling is a frequent event in sporadic 114 
cSCC. We employed targeted 454 pyrosequencing of TGFBR1 and TGFBR2 in 91 human 115 
primary  cSCC samples (Supplementary Table 2) and 21 human cell lines derived from 116 
primary cSCC15,  all of which were recently sequenced for common genetic alterations6. 117 
Using a percentage variance criterion of >10% we detected mutations of TGFBR1 in 22% and 118 
TGFBR2 in 30% of primary cSCC samples and 14% of cell lines (Fig. 1b,c and Supplementary 119 
Data 3). Overall, mutation of TGFβ receptors occurred in 43% of primary cSCC samples. 120 
These mutational events were only surpassed in frequency by mutations in NOTCH1/2 121 
(86%), and this time TP53 (63%) (Fig. 1b, Supplementary Data 4, Ref 6). In sporadic cSCC 122 
oncogenic activation of RAS only occurred in 9% of samples (Fig. 1b, Supplementary Data  4, 123 
Ref 6). We then sequenced normal blood samples from 8 patients with sporadic cSCC whose 124 
lesions harboured mutations in TGFβ receptors (Supplementary Data  3) and found no TGFβ 125 
receptor mutations. Next we prospectively collected a further Dundee cohort of 7 primary 126 
cSCC samples with complementary matched normal distant and perilesional skin 127 
(Supplementary Table 3). This cohort demonstrated a comparable spectrum of mutation in 128 
our selected gene panel and in both TGFβ receptors (Fig. 1d, Supplementary Data 5). TGFβ 129 
receptor mutations were again not identified in either distant or perilesional skin. To assess 130 
the potential lesion specific, non-germline significance of TGFβ receptor mutations, we 131 
interrogated the pyrosequencing analysis in depth from all of the samples containing normal 132 
matched tissue (Supplementary Data 6). We observed only 8 variant reads out of 1348 133 
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reads in total in 4 out of 25 matched normal sample reads. Three of these samples were 134 
from peri-lesional skin and likely reflect rare contaminating tumour cells. In comparison we 135 
observed 237 variant reads out of 1340 reads in the tumour samples. Employing Fisher’s 136 
exact 2 sided tests to compare variant allele frequencies (VAFs) in matched samples, we 137 
determined that 17/25 of the TGFβ receptor mutations reached tumour specific VAF 138 
statistical significance confirming the lesion specific non-germline nature of these mutations 139 
(Supplementary Data  6).   140 
 141 
TGFBR1 and TGFBR2 mutations are driver events in human cSCC 142 
Next we examined a further cohort of 30 primary cSCC samples with matched normal tissue 143 
(Supplementary Table 4) employing next generation WES (see Methods) and interrogated in 144 
detail NOTCH1, NOTCH2, TP53, CDKN2A, HRAS, KRAS, NRAS, TGFBR1 and TGFBR2 genes for 145 
mutational and copy number changes (Fig. 2a and Supplementary Data 7). We observed 146 
alterations in all of these genes with a similar frequency to that of our previous 454 147 
pyrosequencing analysis. None of the mutational events were found in the matched normal 148 
samples and all except two of these were statistically significant (Fisher’s exact t-test) 149 
(Supplementary Data 8). Importantly we observed changes in TGFBR1 in 30% of the 150 
samples and changes in TGFBR2 in 40% of the samples with a combined alteration in 53% of 151 
samples, confirming a frequent alteration of TGFβ receptor genes in cSCC. Copy number 152 
analysis also revealed that loss of heterozygosity (LOH) occurred in both TGFBR1 and 153 
TGFBR2 genes including in tumors with missense mutations in TGFBR2 (Fig. 2a, 154 
Supplementary Data  8). Somatic single nucleotide variants (SNVs) of TGFβ receptors were 155 
detected in 30% of our samples consistent with our 454 pyrosequencing analysis and the 156 
recent sequencing analyses of two North American cSCC cohorts which, when combined, 157 
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detected TGFβ receptors protein altering SNVs in 15.7% of samples16,17. Given the high 158 
mutational burden of cSCC, it is probable that many mutations identified will be passenger 159 
mutations with no functional consequence for tumorigenesis. We investigated the potential 160 
functional consequence of the mutations detected by WES employing MutsigCV18 and 161 
IntOgen analysis19. MutsigCV detected TP53, CDKN2A, NOTCH1 and NOTCH2 as significant 162 
drivers but no RAS genes and IntOgen detected TP53, CDKN2A NOTCH1 and HRAS as 163 
significant drivers but did not identify NOTCH2, KRAS or NRAS (Supplementary Data 9). 164 
Neither analysis detected TGFBR1 or TGFBR2 individually as significant drivers 165 
(Supplementary Data 9), but IntOgen pathway analysis revealed TGFβ signaling as a 166 
significantly altered signaling pathway (Oncodrive-fm functional impact bias, FM bias19, 167 
p=0.0019, Supplementary Data 10). We assessed the clonality of our candidate driver genes 168 
using the ABSOLUTE algorithm20. WES data were of sufficient quality for 24/30 exomes and 169 
ABSOLUTE analysis revealed purity and ploidy estimates ranging from 0.2-0.73 and 1.78-170 
5.79 respectively (Supplementary Data 11). ABSOLUTE clonality analysis indicated that all 171 
NOTCH1, CDKN2A, and RAS mutations were clonal as were all bar one TP53, three NOTCH2 172 
and one TGFBR1 mutation which were subclonal (Fig. 2b,c, Supplementary Data 12). 173 
Mutations present in nearly all tumor cells (clonal) would suggest early events and therefore 174 
represent initiating “driver” genes as appears to be the case here for NOTCH1, NOTCH2, 175 
CDKN2A, HRAS, KRAS, TP53 and importantly both TGFBR1 and TGBFR2. 176 
 177 
Having established the likely driver event of mutation of TGFBR1 and TGFBR2 in our WES 178 
data set we extended this analysis to include our samples assessed by targeted sequencing. 179 
We first calculated average percentage VAFs for our candidate drivers and these ranged 180 
from 48.7% for CDKN2A to 20% for TGFBR1 (Fig. 3a). TGFBR1 VAF was significantly lower 181 
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than that of CDKN2A, TP53, HRAS, NOTCH1, TGFBR2 and NOTCH2 but not KRAS and NRAS 182 
(Fig. 3a, Supplementary Data 13).  TGFBR2 VAF was only statistically significantly lower than 183 
CDKN2A and TP53 but equivalent to KRAS, NOTCH2 and NRAS (Fig. 3a, Supplementary Data 184 
13).   The VAFs of the TGFβ receptors are  of a similar range to those observed in other cSCC 185 
driver genes. UV light is the major oncogenic stimulus of cSCC and the % of mutations 186 
conforming to a UV signature (C-T or G-A transitions) of our candidate drivers ranged from 187 
79.7% in CDKN2A to 30.4% in HRAS (Fig. 3b) with mutations in both TGFβ receptor genes 188 
lying within this range. VAFs were statistically significantly higher for UV signature mutations 189 
for NOTCH2, CDKN2A and TGFBR2 (Supplementary Fig. 1a, Supplementary Data 14). If 190 
these candidate genes represent potential driver genes then the mutational consequence 191 
should be predicted to change protein function. We classified these mutations as potentially 192 
damaging if they were predicted to be so by at least two of the four mutation function 193 
prediction programmes SIFT21, PolyPhen-222, Provean23 and Mutation Assessor24 or were a 194 
splice site or PTC mutation (Fig. 3c). Damaging mutation rates ranged from 89% for TP53 to 195 
53.5% for TGFBR1 (Fig. 3c, Supplementary Data 15-23) were statistically significantly higher 196 
for those with a UV signature for NOTCH2, TGFBR2 and TP53 (Fig. 3d, Supplementary Data 197 
24) and damaging mutations had higher VAFs for NOTCH2, CDKN2A, TGFBR2 and NOTCH1 198 
(Supplementary Fig. 1b, Supplementary Data 25). Together our data suggest that 199 
approximately 70% of TGFBR2 and 50% of TGFBR1 mutations will alter protein function with 200 
the potential to drive cSCC development. In its entirety our analysis conservatively 201 
estimates functionally relevant TGFBR1 and TGFBR2 mutations in ~10% and ~16% of 202 
samples respectively and therefore 20% of cSCC samples could harbour damaging 203 




TGFβ receptor mutation inactivates canonical Smad signaling 206 
Identified missense and nonsense mutations were found throughout the coding exons of 207 
both TGFBR1 and TGFBR2, occurring in the extracellular and kinase domains of each protein 208 
(Fig. 3e). Structural analysis of the extracellular domains of TGFBR1 (Supplementary Fig. 2) 209 
and TGFBR2 (Supplementary Fig. 3) indicated mutations occur in, or in close proximity to, 210 
highly conserved disulphide bonds, ligand interaction motifs and/or receptor interaction 211 
motifs. These findings suggest significant potential for loss of function25,26.  212 
 213 
TGFβ signals via activation of a heterotetrameric complex of TGFBR2:TGFBR1, resulting in 214 
TGFBR1-kinase driven c-terminal phosphorylation of SMAD2 and SMAD327. Once 215 
phosphorylated (PO4), SMAD2 and SMAD3 form hetero-oligomeric complexes with the co-216 
Smad SMAD4, accumulate in the nucleus and regulate gene expression of hundreds of 217 
target genes28,29.  Activity of SMAD-dependent reporter gene constructs and steady state 218 
levels of SMAD2/3 c-terminal phosphorylation can be used as measures of canonical TGFβ 219 
signaling. To assess the functional consequence of these TGFβ receptor mutations we 220 
generated a panel of four TGFBR1 and five TGFBR2 mutant expression plasmids from 221 
mutations identified in our original targeted sequencing series. We assayed each mutant 222 
receptor for functional activity in transient transfection reporter gene assays. TGFBR1 223 
expression plasmids were co-transfected into TGFBR1 null MEFS30 and TGFBR2 expression 224 
plasmids were co-transfected into TGFBR2 null T47D breast cancer cells, in addition to the 225 
TGFβ responsive reporter construct SMAD7 Pomoter-luciferase31 (Fig. 4a and Fig. 4b 226 
respectively). Wild type TGFβ receptor expression elevated reporter activity over empty 227 
vector controls, which was further elevated by TGFβ treatment (Fig. 4a,b). We confirmed 228 
this activity was dependent on intact SMAD binding elements in the SMAD7 promoter 229 
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(Supplementary Fig. 4a,b). The TGFBR1 mutants H331R and W277C and all of the TGFBR2 230 
mutants (S474F, C486R, C96R, R2323W, A556T) failed to efficiently activate the reporter 231 
gene, despite similar levels of expression of the receptors, as assayed by western blotting 232 
(Fig. 4a,b). These findings indicate that mutation of TGFBR1 and TGFBR2 in cSCC frequently 233 
results in a loss of ability to activate canonical SMAD signaling. To demonstrate corollary of 234 
these findings in primary human tissue we then established conditions to monitor c-235 
terminal PO4-SMAD3 levels using a c-terminal Ser433/Ser435 PO4-SMAD3 specific antibody 236 
in cSCC by immunohistochemistry (IHC) (Supplementary Fig. 5). We measured PO4-SMAD3 237 
activity in 8 primary tumors harbouring wild type receptors and 8 primary tumors 238 
harbouring mutant TGFβ receptors with a combined VAF of >20% (Supplementary Data 26). 239 
Wild type tumors exhibited readily detectable PO4-SMAD3 activity whereas mutant tumors 240 
showed significantly reduced PO4-SMAD3 activity (Fig. 4c, Supplementary Fig. 6), consistent 241 
with our observation that mutation of TGFβ receptors results in loss of canonical SMAD 242 
signaling activity. Both wild type and mutant tumors exhibited heterogeneity of staining 243 
consistent with our previous observations that cSCC is heterogenous in nature6 and with the 244 
VAFs observed in mutant tumors. 245 
Finally, we used primary human cSCC cell lines to assess whether TGFβ receptor mutation 246 
results in a loss of TGFβ signaling. Exogenous treatment of normal human keratinocytes 247 
(NHK) with TGFβ1 resulted in a dose dependent decrease in cell proliferation (Fig. 4d). The 248 
TGFBR2 mutant harbouring cell lines SCCIC8 and SCCIC12 (Supplementary Data 3) failed to 249 
respond to exogenous TGFβ stimulation by either PO4-SMAD activation (Supplementary Fig. 250 
7) or by any effect on cell proliferation (Fig. 4d). Co-transfecting these TGFBR2 mutant cells 251 
with either empty vector, or wild type TGFBR2 expression plasmids in addition to a GFP 252 
expression plasmid, we measured cell proliferation in real-time using Incucyte-ZoomTM 253 
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imager over 6 days. Cell proliferation of the GFP+ve cells indicated that cells expressing wild 254 
type TGFBR2 proliferated at a slower rate in the presence of exogenous TGFβ (Fig. 4e). The 255 
degree of inhibition was commensurate to the degree of restoration of SMAD activity as 256 
measured using the multimerised SMAD binding element reporter gene CAGA12-Luciferase32 257 
(Supplementary Fig. 7c,d). These findings indicate that re-expression of wild-type TGFBR2 258 
restores canonical TGFβ signaling and proliferative inhibition, confirming mutational loss of 259 
TGFβ tumor suppressive activity. 260 
 261 
Matrix  cells exhibit active TGFβ signaling 262 
Given this potential aetiological loss of TGFβ signaling, we sought to identify sites of active 263 
TGFβ signaling in normal skin to gain insight into the cellular origin of  cSCC RAF inhibitor 264 
induced lesions. PO4-SMAD3 activity was barely detectable by IHC analysis in normal human 265 
epidermis (Supplementary Fig. 8) but showed strong immunoreactivity in the hair matrix 266 
zone of anagen hair follicles (Fig. 5a, Supplementary Fig. 8). PO4-SMAD3 positivity was also 267 
detected in the hair matrix of anagen hair follicles in mouse back skin (Fig. 5a). In anagen, 268 
the hair follicle transit-amplifying (TA) cells are localized in the matrix and are positive for 269 
Sonic hedgehog (SHH)11. Elegant studies by the Blanpain group have demonstrated these 270 
cells are unable to act as a cell of origin for papilloma formation, even when both oncogenic 271 
Kras and Tp53 were targeted11. This suggests that these PO4-SMAD3+ve hair matrix cells are 272 
unlikely to be the cell of origin for the rapid cSCC observed in humans following RAF 273 
inhibitor treatment. To investigate this in the mouse, we tested if Tgfbr1 deletion could 274 
permit the transformation of TA cells. RAF inhibitors stimulate paradoxical activation of the 275 
MAPK pathway in cells with wild-type BRAF harbouring upstream pathway activation, via 276 
mechanisms such as: up-regulated receptor tyrosine kinases, oncogenic RAS via RAF dimer 277 
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formation33-35, or relief of inhibitory auto-phosphorylation36. Circumventing pharmacological 278 
enhancement of MAPK signaling in the presence of mutated RAS, we modelled 279 
hyperactivation of the MAPK pathway in the SHH+ve compartment by targeting downstream 280 
oncogenic BrafV600E and oncogenic activation of KrasG12D. We crossed our previously 281 
described LSL-BrafV600E mice37, which allow inducible expression of BrafV600E from the 282 
endogenous Braf gene, with the ShhCREER strain38. This permits tamoxifen inducible 283 
activation of the Cre recombinase in SHH+ve cells. To assess the role of TGFβ signaling in the 284 
SHH+ve cells, we then crossed these animals with Tgfbr1fl mice30 (Supplementary Fig. 9a,b). 285 
No tumors formed in the skin of ShhCREER BrafV600E and ShhCREER BrafV600E Tgfbr1fl/+ mice 286 
(Fig. 5b, Supplementary Fig. 10a,b). A small percentage of ShhCREER BrafV600E Tgfbr1fl/fl mice 287 
developed minimally proliferative papillomatous lesions (as evidenced by low level BrdU 288 
staining) mainly in the lips, but only at long latency (Fig. 5b, Supplementary Fig. 10c). No 289 
mice developed cSCC. Mice failed to develop any skin lesions following oncogenic activation 290 
of KrasG12D with or without deletion of Tgfbr1 in this cell compartment (Fig. 5c). Together 291 
these studies indicate that the SHH+ve cells are unlikely to be the cell of origin for either 292 
rapid onset vemurafenib-induced cSCC, or sporadic cSCC.  293 
 294 
TGFβ signaling is active in telogen bulge stem cells 295 
Approximately 90% of human hair follicles are present in the anagen phase of the hair cycle 296 
with the remaining 10% existing in catagen or the resting telogen phase. Analysis of human 297 
telogen hair follicles revealed highly localised PO4-SMAD3 staining in the bulge stem cells, 298 
characterised in part by KERATIN 15 staining (Fig. 6a). This pattern was recapitulated in 299 
mouse telogen hair follicles (Fig. 6b), characterised by the expression of the stem cell 300 
marker LGR539. To investigate further, we used the Lgr5-EGFP-Ires-CREERT2 knockin mouse 301 
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(hereafter termed Lgr5CREER), where the endogenous Lgr5 promoter controls expression of 302 
enhanced green fluorescent protein (EGFP) and the CREERT2 fusion protein40. IHC analysis 303 
for GFP revealed a staining pattern similar of that observed for PO4-SMAD3 (Fig. 6c). 304 
Furthermore, co-immunofluorescence revealed LGR5+ve cells (stained for EGFP) are highly 305 
enriched for both PO4-SMAD3 and TGFBR1 (Fig. 6d and Supplementary Fig. 11).  306 
 307 
Recent studies indicate that the dermal papilla may provide a source of TGFβ2, activating 308 
SMAD signaling in overlying hair germ stem cells41. We sorted epithelial EGFP positive 309 
LGR5+ve stem cells from murine back skin. Quantitative reverse-transcriptase PCR (Q-RTPCR) 310 
analysis  revealed LGR5+ve cells express enhanced levels of Tgfbr1, Tgfb1 and Tgfb3 mRNA 311 
when compared to LGR5-ve cells, with negligible amounts of Tgfb2 (Fig. 6e). Expression of 312 
Tgfbr2 was readily detected in GFP+ve and GFP-ve compartments (Fig. 6e). This indicates 313 
enriched autocrine TGFβ signaling in the LGR5+ve compartment. We observed high levels of 314 
the TGFβ target gene Smad742 in LGR5+ve cells (Fig. 6e). Together these findings indicate that 315 
autocrine TGFβ signaling is highly localised to the LGR5+ve hair follicle bulge stem cells in the 316 
mouse, and the KERATIN 15+ve hair follicle bulge stem cells in humans, and that this cell 317 
compartment may give rise to both vemurafenib-induced and sporadic cSCC.  318 
 319 
Rapid cSCC formation from Lgr5+ve stem cells 320 
To investigate the consequence of hyperactivation of the MAPK pathway coupled with 321 
ablation of TGFβ signaling in LGR5+ve stem cells we crossed the Lgr5CREER mice with the LSL-322 
BrafV600E mice (Supplementary Fig. 9c), or LSL-KrasG12D mice and Tgfbr1fl mice 323 
(Supplementary Fig. 9d). Loss of TGFβ signaling alone was not sufficient to initiate 324 
tumorigenesis (Fig. 7a). Targeted activation of BRAF to LGR5+ve cells resulted in decreased 325 
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survival, with all mice euthanized 300-days post induction of the transgene by injection of 326 
tamoxifen (Median survival 276 days). Whilst 6 out of 14 mice succumbed to adrenal 327 
tumors, 50% of these mice presented with papillomas consistent with LGR5 expression in 328 
murine skin (Fig. 7a,c). However, the long latency period suggests Braf mutation requires 329 
additional events to facilitate papilloma development. The combined targeted inactivation 330 
of one allele of Tgfbr1 reduced survival (median survival 231 days) and enhanced both the 331 
number of mice with skin lesions, and the number of lesions per mouse (Fig. 7a,c and 332 
Supplementary Fig. 12a). Inactivation of both Tgfbr1 alleles significantly increased  the 333 
numbers of tumor per mouse and dramatically shortened both skin tumor free survival (all 334 
mice developing skin lesions within 63 days of induction) and overall survival (median 335 
survival 51 days) (Fig. 7a,c and Supplementary Fig. 12a). Phenotypically these lesions 336 
appeared as differentiated papillomas in Tgfbr1 wild-type and heterozygous mice (Fig. 7c-e 337 
and Supplementary Fig. 12b). Remarkably, in the homozygous Tgfbr1fl/fl mice tumors 338 
appeared as ulcerative cSCC (Fig. 7c and Supplementary Fig. 12b). Elegant work by the 339 
Blanpain and Jensen laboratories10,11 have shown when Kras is targeted to skin stem cells, 340 
there is long latency to papilloma formation (similar to the BrafV600E allele described here) 341 
and most of these lesions form around areas associated with wounding. Targeted activation 342 
of Kras alone mainly failed to produce skin lesions, however, when we targeted inactivation 343 
of both alleles of Tgfbr1 and the KrasG12D mutation to the LGR5+ve compartment, mice 344 
developed rapid cSCC with kinetics comparable to BrafV600E mice (Fig. 7b,c). Additionally, 345 
KERATIN1 (Fig. 7d) and KERATIN 5 staining (Fig. 7e) revealed that cSCC lesions in both the 346 
Braf and Kras mice are poorly differentiated cSCC. Importantly these lesions were highly 347 
proliferative (Supplementary Fig. 12c) and never progressed via a papillomatous stage, 348 
recapitulating the rapid cSCC onset observed in humans12,13. PO4-SMAD3 activity exhibited a 349 
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dose dependent reduction in tumors isolated from these mice, indicating loss of TGFβ 350 
signaling (Supplementary Fig. 12d,e). Q-RTPCR analysis of these tumors revealed loss of 351 
Tgfbr1 expression (Supplementary Fig. 12f) without any significant change in ligand mRNA 352 
expression (Supplementary Fig. 13).  353 
 354 
Skin tissue compartmentalization has been recently proposed as a mechanism involved in 355 
tissue maintenance10. To test if Tgfbr1 deletion perturbed such compartmentalization, we 356 
lineage traced LGR5+ve cells by intercrossing Lgr5CreER with the RosaLSL-RFP reporter mice 357 
(Supplementary Fig. 9e). We observed that RFP positive cells were confined to the hair 358 
follicle39 and were never detected in the sebaceous gland, or interfollicular epidermis 359 
regions of Lgr5CreER BrafV600E, or Lgr5CreER BrafV600E  Tgfbr1fl/+ mice, at early time points post 360 
induction (Supplementary Fig. 14).  The cSCC arising within Lgr5CreER BrafV600E Tgfbr1fl/fl 361 
mice were fully recombined and RFP positive. In the normal skin comparator for these 362 
tumours, but also at earlier time points, the LGR5+ve cells and their progeny were localised in 363 
their normal compartment (Supplementary Fig. 14). These results indicate that 364 
perturbation of TGFβ signaling is insufficient to disrupt compartmentalization, but acts as a 365 
tumour suppressor in LGR5+ve stem cells.  366 
 367 
Given the infrequent coincident activation of RAS genes and mutational inactivation of TGFβ 368 
receptors in sporadic cSCC we finally sought to model this disease by inactivating TP53 369 
function coupled with deletion of Tgfbr1 in LGR5+ve cells (Supplementary Fig. 9f). Knockin of 370 
mutant Tp53 (R172H) coupled with deletion of the wild type allele had no discernible 371 
phenotype (Fig. 8a). Heterozygous knockin or deletion of Tp53 coupled with homozygous 372 
deletion of Tgfbr1resulted in the emergence of skin tumours in a few mice (30% and 20% 373 
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respectively) with long latency. Combined knockin of mutant Tp53 with deletion of the wild 374 
type allele of Tp53 coupled with deletion of Tgfbr1resulted in skin tumor development in 375 
81% of mice with increased tumor number at a shorter latency (Fig. 8a,b). These tumors 376 
exhibited loss of differentiation expressing low levels of KERATIN 1 and higher levels of 377 




Recent studies have revealed an exceptionally high mutation burden (50 mutations per 382 
megabase of DNA6) in cSCC6,16,17. This rate is second only to that of the commonest skin 383 
malignancy basal cell carcinoma43. This translates to potentially thousands of mutations per 384 
tumor, providing a particular challenge in identifying driver mutations. This challenge is 385 
further compounded by varying efficiencies in deep sequencing technologies and profound 386 
tumor heterogeneity2,6,44,45. Our studies here reveal that targeted deep sequencing using 387 
fluidigm PCR amplification and Roche 454 pyrosequencing can provide a robust platform to 388 
identify mutations in NOTCH1, NOTCH26,TGFBR1 and TGFBR2 genes. This approach has also 389 
implicated alterations of NOTCH, TP53 and RAS in cSCC tumor development6,46. We further 390 
these studies by revealing mutation of TGFβ receptors in 43% of sporadic human cSCC and 391 
28% of vemurafenib-induced skin lesions (Fig. 1). The prevalent tumor initiating event in 392 
cSCC is UV-induced damage, which manifests as C-T and G-A transitions39. Approximately 393 
68% of all nucleotide changes observed in our cSCC samples present with this signature6. 394 
Analysis of mutational signatures in TGFβ receptors reveals that 42% conform to a UV 395 
signature (Fig. 3b, Supplementary Data 13). This figure increases to 56.1% when scored as 396 
possibly damaging events via protein function prediction programmes (Fig. 3d, 397 
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Supplementary Data 24). This indicates that UV damage may also be responsible for 398 
inactivation of TGFβ receptors. Mutation prediction programmes scored 53.5% of TGFBR1 399 
and 71.1% of TGFBR2 receptor mutants as damaging indicating that approximately 20% of 400 
cSCC harbour TGFβ receptor inactivation (Supplementary Data 15-16, Fig. 3c). Subsequent 401 
functional analysis of 4 TGFBR1 mutants and 5 TGFBR2 mutants indicated that half of the 402 
TGFBR1 mutants and all five TGFBR2 mutants were loss of function for canonical Smad 403 
signaling and that tumors harbouring TGFβ receptor mutations had reduced PO4-SMAD3 404 
activity (Fig. 4). Restoration of TGFBR2 expression to TGFBR2 null cell lines restricted cell 405 
proliferation (Fig. 4). Taken together these findings indicate that loss of TGFβ tumour 406 
suppressor function is a common event in cSCC.  407 
 408 
The assessment of VAFs provides an indication of the clonality of tumors and aids the 409 
potential identification of early driver mutationss during tumor development2. We ranked 410 
mutational events by potential order of occurrence in the 7 genes we have previsouly 411 
implicated in cSCC development and TGFβ receptors by measurement of VAF 412 
(Supplementary Data 15-16). These analyses indicate that potentially damaging mutations 413 
in TGFBR1 occur early in 25% of tumors harbouring these mutations and in 42% of tumors 414 
harbouring potentially damaging TGFBR2 mutations. Although this analysis is limited to the 415 
9 genes studied in-depth here (but importantly including NOTCH genes previously identified 416 
as gatekeeper mutations in cSCC6), 11 samples exhibited TGFβ receptor mutations with the 417 
highest VAF indicating that this could be an initiating event in the development of cSCC. 418 
Strong support for this hypothesis comes from ABSOLUTE clonality analysis of our WES 419 
samples which revealed that 7/8 TGFβ receptor mutations were clonal and represent 420 




Several of our samples display VAFs of 10-20% for the TGFβ receptors  which is not too 423 
dissimilar to the VAFs of the other known cSCC tumor suppressors studied here and likely 424 
reflects the heterogeneous nature of cSCC. It is however an intriguing possibility that in 425 
some cases low TGFβ receptor VAF may reflect spontaneous regression of TGFβ receptors 426 
mutant clones as observed in multiple self-healing squamous epithelioma (MSSE) patients 427 
who harbour germline mutations in TGFBR147. TGFβ signaling has been demonstrated to 428 
play both positive and negative roles in cSCC development in various mouse models48 acting 429 
to limit tumor cell proliferation but also to promote tumor initiating capacity and drug 430 
resistance49. Effects are dependent on the timing of aberrant TGFβ signaling and the 431 
cooperating oncogenic driving events (reviewed in48,50-52). We provide evidence that a dose-432 
dependent loss of TGFβ signaling drives tumor progression - emphasising its role as a major 433 
tumor suppressor in the skin. Although the cell of origin in cSCC in humans remains poorly 434 
defined3, our observations indicate that tumors can initiate efficiently and rapidly from 435 
LGR5+ve stem cells compared to TA cells, and mutational modulation of two signaling 436 
pathways within this cellular compartment is sufficient to drive rapid progression directly to 437 
carcinoma, without the need for protracted tumour evolution. The kinetics of this event 438 
mimic exactly that observed during development of cutaneous lesions in RAF inhibitor 439 
treated patients12,13. Intriguingly this rapid process requires MAPK pathway activation as 440 
targeted intereference with TP53 fu nction coupled with Tgfbr1 loss results in the 441 
development of skin tumours with long latency.  Importantly our studies revealed highly 442 
localised TGFβ signaling in  KERATIN 15+ve  bulge stem cells  in human telogen hair follicles, 443 
mirrored exquisitly the location of specific autocrine TGFβ signaling activity identified in 444 
LGR5+ve bulge stem cells of murine telogen hair follicles. It has been proposed that stem cell 445 
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quiescence acts as a tumor suppresive mechanism in murine skin and that LGR5+ve stem cells 446 
are refractory to oncogenic transformation53. Our data clearly indicate that oncogenic 447 
activation of the RAS/RAF/MAPK pathway, or TP53 modulation, coupled with loss of TGFβ 448 
signaling, is capable of leading to  tumor development from this compartment. As we 449 
demonstrate that mutational inactivation of TGFβ receptors is a frequent event in human 450 
cSCC, and that TGFβ signaling is highly localised to stem cells in normal skin, we propose 451 
that these cells represent a cell of origin for human cSCC. It remains possible that loss of 452 
TGFβ signaling may also contribute to cSCC development from other cell compartments in 453 
the skin and this warrants further investigation.  454 
 455 
Our data, both in human and mice, indicate that TGFβ signaling inactivation can be an 456 
initiating event in sporadic cSCC. This is clearly the case in MSSE where germline loss of 457 
function mutations in TGFBR1 have been identified as the underlying genetic lesion47. We 458 
speculate that activation of the RAS/RAF/MAPK pathway, or p53 modulation, may be a 459 
cooperating event in the development of this disease and that these tumors may originate 460 
from the bulge stem cell compartment.  TGFβ signaling inactivation may also occur following 461 
the acquisition of other driving mutational events and act as a limiting factor for tumor 462 
development. Intriguingly, initial clinical trials targeting systemic TGFβ inhibition with 463 
GC1008 (a pan-TGFβ neutralising antibody) have also reported the occurrence of 464 
spontaneous cSCC as a side effect54. This provides further compelling support for the tumor 465 







Samples. Ethical approval for this investigation was obtained from the East London and City 471 
Health Authority and the Tayside Tissue bank local ethics committee and the study was 472 
conducted according to the Declaration of Helsinki Principles. All patients participating in 473 
this study were from dermatology and plastic surgery units in the UK and all provided 474 
written, informed consent. Punch biopsies of cSCC tissue were collected and processed as 475 
previously reported6.  Normal human keratinocytes were isolated from normal skin samples 476 
according to previously published protocols55. Human tumor cell lines SCCIC1, SCCIC4, 477 
SCCIC8, SCCIC15, SCCIC12, SCCIC18, SCCIC19, SCCIC21, SCCT1, SCCT2, SCCT6, SCCT8, PM1, 478 
MET1, MET4,  SCCT9, SCCT10, SCCT11,  RDEBSCC2, RDEBSCC3, RDEBSCC4 and NTERT cells 479 
were established by our laboratories and were cultured as described15. TGFBR1  null MEFs30 480 
and T47D cells (ATCC) were maintained in DMEM and RPMI supplemented with 10% FCS 481 
respectively. Mycoplasma contamination checks were carried out on all cultures as routine 482 
and all lines were confirmed mycoplasma negative. 483 
 484 
454 sequencing. TGFBR1 and TGFBR2 primers were designed and validated by Fluidigm 485 
(Fluidigm Corporation, San Francisco, CA) as per recommended guidelines for Roche 486 
Titanium sequencing (Roche, Mannheim, Germany). Primers for NOTCH1, NOTCH2, TP53, 487 
CDKN2A, HRAS, KRAS and NRAS were previously described6 and all primer sequences are 488 
listed in Supplementary Data 27. Each primer included sample-specific Fluidigm 454 barcode 489 
primer and adapter sequences. Sequencing was performed in the same manner as our 490 
previous study56. Briefly for thermal cycling a Fluidigm FC1 Cycler was used. The libraries 491 
were normalized and pooled prior to purification using Agencourt AMPure XP system 492 
(Beckman, UK). Library components were clonally amplified utilising the GSJunior emPCR 493 
22 
 
Lib-A Kit (Roche) by inputting 1 molecule of library DNA per capture bead. Pyrosequencing 494 
was done using the GS Junior system (Roche/454 Life Sciences).  495 
 496 
454 variant analyses. Variant analysis was performed as previously described6. Briefly,  497 
reads were mapped to the hg19 build of the human genome using LASTZ via the public 498 
GALAXY instance and filtered to exclude those mapping to <100 loci using tools available 499 
through GALAXY.  500 
 501 
Coding Variants and splice site detection. Pileup files were generated and filtered using 502 
SAMTools57. Variants present in a single read or less than 10% of the total reads were 503 
excluded using a custom java program available from https://github.com/mattsouth/laszt-504 
variant-filter (last accessed 6th May 2013). Coding variants were called against the RefSeq 505 
gene list using the amino acid tool via the public GALAXY instance. Variants present in <3 506 
reads were excluded. Variants present in >1 independent sample and adjacent to a 507 
homopolymer >3 bases were excluded unless present in COSMIC58. Variants present in >30 508 
samples were excluded unless present in COSMIC. All variants present in the exome variant 509 
server database (http://evs.gs.washington.edu/EVS/) were excluded unless present in 510 
COSMIC. Splice sites were called from the pileup variant list if present in >4 reads and within 511 
2 bases of Refseq coding sequence using Excel (Microsoft Inc., CA). 512 
 513 
Whole exome sequencing data analysis. 20 previously published cSCC whole exomes6 were 514 
re-analysed with the addition of 10 new cSCC whole exomes with the overall mean coverage 515 
of 63x (Supplementary Table 4), using a previous pipeline59.  SNVs and short indels were 516 
identified using the Strelka pipeline60 with a minimum coverage of 10 reads at the targeted 517 
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sites. Annotation of somatic variants was performed using the Oncotator tool61. Mutations 518 
in our targeted genes were further identified across the 30 cSCC WES samples. 519 
 520 
Copy number analysis using WES data. Two independent approaches were applied. First, to 521 
generate SNP and indel variant genotyping information, the tumor-normal pair was 522 
processed together against the reference genome using the VarScan2 germline variants 523 
calling method mpileup2cns62. The minimum coverage for identified sites was 10 reads for 524 
both tumor and normal. Next the logR and BAF (B-allele frequency) files were created based 525 
on the tumor-normal pair genotyping information, with the depth information normalized 526 
by dividing the depth of each variant by the median depth across all variants. The ASCAT R 527 
packages63 were then used to perform allele-specific copy number analysis to identify copy 528 
number aberrations (CNA) and loss-of-heterozygosity (LOH) regions. The second approach 529 
was based on numbers of reads aligned to each exon between the tumor and normal pair. 530 
VarScan2 copy number calling method was firstly applied. Raw copy number calls were 531 
adjusted as previously reported64. Finally results from the two approaches were cross-532 
compared to produce the final CNA and acquired uniparental disomy (aUPD) calls for 533 
targeted genes. 534 
 535 
Identification of potential cancer drivers and significantly mutated pathways. Based on all 536 
mutations identified from the 30 cSCC WES dataset, we used the IntOGen platform19 to 537 
identify significantly mutated genes and pathways, based on the significance (p-value) of the 538 
FM bias (i.e., the bias toward the accumulation of mutations with high functional impact). 539 
The significantly mutated signaling pathways (based on the IntOGen Oncodrive-fm 540 
functional impact bias, FM bias p < 0.05) ) were further selected (Supplementary Data 10). 541 
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MutsigCV18 was also used to detect significant genes with point mutations above the 542 
background mutation rate. 543 
 544 
Estimating the clonality of mutations. For the somatic mutations of TGFBR1/2, TP53, 545 
CDKN2A, NOTCH1/2 and RAS genes identified by WES (Supplementary Data 7), we further 546 
classified them as clonal or subclonal on the basis of the posterior probability that the 547 
cancer cell fraction (CCF) exceeded 0.95 using ABSOLUTE20. Numbers of reads supporting 548 
the reference and alternative alleles were extracted, and the copy number segmentation 549 
files were generated based on the DNAcopy CBS segments using WES data. Mutations with 550 
the somatic clonal probability > 0.5 were classified as clonal with high confidence. Those 551 
mutations with clonal probability > 0.25 but with very small subclonal probability scores 552 
were also called clonal (Supplementary Data 12). Tumor purity and ploidy were also 553 
estimated (Supplementary Data 11). For samples with TGFBR1/2 mutations, CCFs for 554 
TGFBR1/2 were further compared to those for other genes to determine the clonality 555 
orders. 556 
 557 
Functional prediction of mutations. A combination of four approaches were used to predict 558 
the functional impact of identified mutations by targeted sequencing, (i) SIFT21, which uses 559 
sequence homology and protein conservation to predict the effects of all possible 560 
substitutions at each position in the protein sequence; (ii) PolyPhen-222, which predicts 561 
possible functional impact of an amino acid substitution on the structure and function level 562 
using physical and comparative considerations; (iii) Provean23, which predicts the damaging 563 
effects of SNVs and indels using a versatile alignment-based score; and (iv) Mutation 564 
Assessor24, which measures the functional impact scores for amino acid residue changes 565 
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using evolutionary conservation patterns derived from aligned families and sub-families of 566 
sequence homologs within and between species. Mutations predicted as functional 567 
damaging by at least two of the four approaches were classified being potentially 568 
damaging/deleterious. 569 
 570 
In Vivo analyses. All experiments were performed under the UK Home Office guidelines. 571 
Mice were segregating for C57BL6J and S129 background. Alleles used throughout this study 572 
were: Lgr5-cre-ERT240, ShhCreER38, BrafV600E37, KrasG12D65 , Tgfbr1fl30 and RosaLSL-RFP66. A mix of 573 
males and females were used. Recombination in the Lgr5-cre-ERT2 mouse model was 574 
induced with 1 intraperitoneal (IP) injection of 3 mg Tamoxifen (Sigma) followed by 1 575 
injection of 2 mg Tamoxifen for 3 days. Mice were induced post 7 weeks of age. 576 
Recombination in the ShhCreER mouse model was induced with 1 IP injection of 2.5 mg 577 
Tamoxifen. Mice were induced post 28 days of age. For proliferation analysis mice were 578 
injected with 250 μl of BrdU (Amersham Biosciences) 2 hours before being sacrificed. 579 
 580 
FACS analysis. Epidermis was prepared as previously described67. Briefly, fat was scraped 581 
from the mouse back and left at 37◦C in a dish (dermis down) in 0.25% of Trypsin/EDTA 582 
(Invitrogen) for 90 min. Epidermis was removed using a scalpel and dissociated by pipetting. 583 
Cells were filtered through a 40 µm strainer, centrifuged at 250g for 5 min and washed with 584 
PE (PBS/EDTA). Cells were washed with 0.1% BSA/PE, centrifuged at 250g for 5 min and 585 




Immunohistochemistry. Immunohistochemistry (IHC) was performed on formalin-fixed skin 588 
sections. Standard IHC techniques were used throughout this study. Primary antibodies 589 
were as follows: TGFBR1 (Santa Cruz, V22, 1:100), PO4-SMAD3 (Abcam, EP823Y, (52903), 590 
1:50), GFP (Abgent, 168AT1211, 1:100), KERATIN1 (Covance, AF109, 1:1000), KERATIN 5 591 
(Covance, AF138, 1:4000), KERATIN 15 (Abcam, 80522 (LHK15), 1:1000), KI67 (Thermo, RM-592 
9106-S), BrdU (BD Biosciences, 347580, 1:200;). Mouse PO4-SMAD3 score was performed in 593 
a blinded fashion. For each antibody, staining was performed on at least 3 mice of each 594 
genotype and at least six sections of normal human skin. Representative images are shown 595 
for each staining. PO4-SMAD3 antibody was optimised for IHC use using FFPE embedded 596 
SCCIC4 cells treated with and without recombinant TGFβ1 or the TGFBR1 kinase inhibitor 597 
SB-43154268 (Supplementary Figure 5). PO4-SMAD3 IHC scoring was performed in a blinded 598 
manner using the histoscore method.  599 
 600 
RNA isolation and quantitative PCR RNA was isolated using a Qiagen RNeasy Mini Kit 601 
(Qiagen, Crawly, West Sussex, UK) according to the manufacturer’s instructions. DNA-free 602 
(Ambion/Applied Biosystems, Warrington, UK) was used to remove genomic DNA 603 
contamination according to the manufacturer’s instructions. 1ug of RNA was reverse 604 
transcribed to cDNA using a DyNAmo SYBR Green 2-step qPCR kit (Finnzymes, Espoo, 605 
Finland) in a reaction volume of 20 µl. GAPDH was used to normalize for differences in RNA 606 
input. 607 
 608 
qRT-PCR primers. qRT–PCR primers were as follows. mTgfbr1 F-TGCCATAACCGCACTGTCA, 609 
mTgfbr1 R-AATGAAAGGGCGATCTAGTGATG, mTgfbr2 F-CCGGAA GTTCTAGAATCCAG, 610 
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mTgfbr2 R-TAATCCTTCACTTCTCCCAC, mTgfb1 F-AGCCCGAAGCGGACTACTAT, mTgfb1 R-611 
TTCCACATGTTGCTCCACAC, mTgfb2 F-TTTAAGAGGGATCTTGGATGGA, mTgfb2 R-612 
AGAATGGTCAGTGGTTCCAGAT, mTgfb3 F-CGCACAGAGCAGAGAATTGA, mTgfb3 R-613 
GTGACATGGACAGTGGATGC, mSmad7 F-TCAAGAGGCTGTGTTGCTGT, mSmad7 R-614 
TGGGTATCTGGAGTAAGGAGGA, mGapdh F-GAAGGCCGGGGCCCACTTGA, mGapdh R-615 
CTGGGTGGCAGTGATGGCATGG 616 
 617 
Western Blotting. Cells were lysed directly in 4xSDS sample buffer at 60-80% confluence. 618 
Lysates were subjected to standard SDS-PAGE. Bands were detected using enhanced chemi-619 
luminescence solution (ECL, Amersham). Secondary antibodies used throughout: HRP-620 
conjugated polyclonal goat anti-mouse Ig (Dako, P0448, 1:2000), HRP-conjugated polyclonal 621 
goat anti-rabbit Ig (Dako, P0260, 1:2000). Primary antibodies were PO4-SMAD3 (Abcam, 622 
52903, 1:1000), SMAD3 (Cell Signaling, 9523, 1:1000), TGFBR1 (Santa Cruz, 398 (V22), 623 
1:500), TGFBR2 (Santa Cruz, 17792, (E6), 1:500). For TGFBR2 western blots, lysates were 624 
prepared directly from transfected cells using the Dual-luciferase cell lysis buffer (Promega). 625 
For TGFBR1 western blots, parallel transfections to the luciferase assays were performed 626 
and samples were lysed directly in 4xSDS sample buffer. Original uncropped western blot 627 
scans are also provided (Supplementary Figure 15). 628 
 629 
Plasmids. The full-length wild type human TGFBR1 and pathogenic mutants, amplified with 630 
BglII/NotI restriction sites, were shuttled into pCMV5 mammalian cell expression vectors 631 
onto the BamHI/NotI sites. The full-length wild type human TGFBR2 and pathogenic 632 
mutants were sub-cloned into pCMV5 using the BamHI/NotI restriction sites. Site-directed 633 
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mutagenesis was carried out using the QuickChange method (Stratagene) but substituting 634 
the Taq with KOD Hot Start DNA polymerase (Novagen). All DNA constructs were verified by 635 
DNA sequencing (by the DNA Sequencing Service at University of Dundee; 636 
www.dnaseq.co.uk). GFP expression plasmid was from Amaxa. 637 
 638 
Transient transfection analysis. All transfections were performed in 24-well format in 639 
biological triplicate using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA) according to 640 
manufacturer’s instructions. Cells were transfected overnight with 100ng of reporter gene 641 
(SMAD7 Promoter-Luciferase or CAGA12-Luciferase) and 10ng of internal Renilla-Luciferase 642 
control (pRL-TK, E2241, Promega) with empty vector (pCMV5, 211175, Stratagene), wild 643 
type or mutant TGFβ receptor plasmids (range 150-300ng). Recombinant human TGFβ1 644 
(Peprotech) was dissolved in 4mM HCL/1mg/ml BSA and used at final concentration of 645 
5ng/ml and cells were treated for 4 hours prior to harvest. Luciferase activities were 646 
measured using the Dual Luciferase assay (Promega) and firefly luciferase activity was 647 
normalised to renilla luciferase activity. 648 
 649 
Cell proliferation assays. Cells were seeded at a density of 500-1000 cells/well of 96-well 650 
plates in keratinocyte media (RM+) without growth factors and incubated overnight. Cells 651 
were fed 50μl of medium supplemented with treatment and controls every 2 days until 652 
harvest. All cultures were performed in sextuplet (n=6). Cells were assayed for proliferation 653 
using the CellTitreGloTM  Luminescent Cell Viability assay (NHKs) as per the manufacturer’s 654 
instructions (Promega, UK - Luminesence was measured on a Berthold Orion II microplate 655 




Data availability 658 
The whole exome sequencing data for the 30 samples have been deposited in the European 659 
Genome-phenome Archive (EGA) under accession code EGAS00001001892. The authors 660 
declare that all other relevant data supporting the findings of this study are available within 661 
the article and its supplementary information files. Additional information can be obtained 662 
from the corresponding authors (GJI and OJS). 663 
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 841 
Figure Legends 842 
 843 
Figure 1. TGFβ receptors are frequently mutated in vemurafenib-induced skin lesions and 844 
sporadic cSCC tumors. Mutation frequency, distribution and relationship with pathological 845 
features of skin lesions isolated from vemurafenib treated patients (n=39) (a), sporadic cSCC 846 
(n=91) (b), 21 cSCC cell lines (RDEB = recessive dystrophic epidermolysis bullosa) (c), (a-c, 847 
adapted  from  J Invest Dermatol. (2014) with permission from Elsevier (ref 6) 848 
 and 7 sporadic cSCC tumors (T) and normal distant/perilesional skin samples (N) collected in 849 
Dundee (d). Mutation status for nine genes is indicated and the overall percentage mutation 850 
is shown on the left. Each column represents a single case. Colors correspond to specific 851 
mutations as shown. Details of clinical parameters are included in Supplementary Tables 1-3 852 
and mutations are included in Supplementary Data 1-5. 853 
 854 
Figure 2. Target gene mutation and copy number and clonality analysis in 30 cSCC primary 855 
tumors analysed by whole exome sequencing. (a) Mutation frequency, distribution and 856 
relationship with pathological features from 30 cSCC primary tumors. Mutation and copy 857 
number status (gain, loss and aUPD) for nine genes is indicated and the overall percentage 858 
alteration is shown on the left. Each column represents a single case. Colors correspond to 859 
specific mutations and copy number changes as shown. Split columns indicate where more 860 
than one mutation type is present in a single case. Details of clinical parameters and 861 
mutations are included in Supplementary Table 4 and Supplementary Data 7. (b) 862 
ABSOLUTE clonality analysis of potential driver genes of cSCC indicates that all nine genes 863 
are frequently clonal. (c) Cancer cell fraction clonality analysis indicates clonal and subclonal 864 




Figure 3. Mutational frequencies and spectrum of driver mutations. Ranked driver gene 867 
mutations by (a) % VAF (p-values represent student’s t-test (2-tailed) are shown above the 868 
figure, (b) % UV spectrum (c) predicted mutational consequence of Damaging/Non-869 
damaging and (d) combined UV and damaging analysis (p-values are shown above the figure 870 
and represent Chi-squared Fishers exact-test). For all statistics; * defines statistical 871 
significance (*** p<0.001, ** p<0.01 and * P<0.05). Numbers of samples are contained in 872 
Supplementary Data 13. (e) Domain structures of TGFBR1 and TGFBR2 are shown. Exons are 873 
numbered and functional domains colour coded (see key). SNPs identified in TGFBR1 and 874 
TGFBR2 are labelled in AA sequence [using UniProtKB codes: P-36897-1, TGFBR1, HUMAN 875 
and P37173, P37173-2, TGFBR2_HUMAN] for sporadic cSCC (above) and Vemurafenib 876 
associated cSCC (below). Asterisked SNPs are those found in cSCC cell lines. Amino acid 877 
numbers for TGFBR2 refer to isoform 2. 878 
 879 
Figure 4. Mutation of TGFβ receptors results in loss of function. (a) Indicated TGFBR1 880 
plasmids were co-transfected into TGFBR1 null MEFs and assayed for SMAD7-Promoter 881 
Luciferase (SMAD7-Luc) reporter gene activity and receptor expression levels by western 882 
blot (lower panels) with and without TGFβ stimulation for 4 hours. β-ACTIN is used as a 883 
loading control. EV is empty vector control, WT is wild type. Data are mean +/- s.d., n=3. (b) 884 
Indicated TGFBR2 plasmids were co-transfected into TGFBR2 null T47D cells and assayed for 885 
SMAD7-Promoter Luciferase (SMAD7-Luc) reporter gene activity and receptor expression 886 
levels by western blot (lower panels) with and without TGFβ stimulation for 4 hours. β-887 
ACTIN is used as a loading control. EV is empty vector control, WT is wild type. Data are 888 
mean +/- s.d., n=3. (c) PO4-SMAD3 activity was assessed by IHC in wild type and mutant 889 
35 
 
tumors (n=8, ***= p=0.001, Mann-Whitney U test ) Representative images are shown. Scale 890 
bar, 100 μM. (d) Effects of TGFβ stimulation on growth of NHK and cSCC cell lines. Data 891 
represent Cell Titre GloTM measurement of cell proliferation over the indicated time course 892 
of cells treated with the indicated dose of TGFβ1. Normal human keratinocytes (NHK) and 893 
cell lines harbouring mutant TGFBR2 (SCCIC8, SCCIC12) are shown. Data represent the mean 894 
+/- s.d. n=6. (e) Restoration of wild type TGFBR2 restores growth inhibition. SCC1C8 and 895 
SCCIC12 cells were co-transfected with empty vector control (EV) or wild type TGFBR2 896 
expression plasmids (TGFBR2) and a GFP expression plasmid. Proliferation of GFP+ve cells was 897 
assessed using real-time Incucyte ZoomTM imaging over 6 days. Data represent the mean +/- 898 
s.d. n=6. *, ** and *** = p< 0.05, p<0.01 and p<0.001 respectively (Student’s t-test).  899 
 900 
Figure 5. Transit-amplifying SHH positive cells do not allow cSCC development. (a) PO4-901 
SMAD3 IHC in anagen human (left panel) and mouse (right panel) hair follicles reveals 902 
immunoreactivity in the hair matrix. CTL connective tissue layer, ORS outer root sheath, IRS 903 
inner root sheath, DP dermal papilla. Scale bar, 100 µm (b) Kaplan-Meier survival curve of 904 
ShhCreER BrafV600E (n=13), ShhCreER BrafV600E Tgfbr1fl/+ (n=28) and ShhCreER BrafV600E Tgfbr1fl/fl 905 
(n=39) mice. (c) Kaplan-Meier survival curve of ShhCreER KrasG12D (n=17) and ShhCreER 906 
KrasG12D Tgfbr1fl/fl (n=21) mice. 907 
 908 
Figure 6. TGFβ signaling is active in LGR5+ve stem cells. (a) IHC analysis of PO4-SMAD3 (left 909 
panels) and KERATIN 15 (right panels) in human normal skin. Insert shows strong PO4-910 
SMAD3 staining in the telogen hair follicle KERATIN 15+ve bulge stem cells. Scale bar, 100 µm 911 
(b) IHC analysis of PO4-SMAD3 (IFE inter-follicular epidermis, SG sebaceous gland, BG Bulge, 912 
DP dermal papilla) and (c) LGR5-GFP  in murine skin in the telogen phase of the hair cycle. 913 
36 
 
Scale bar, 100 µm (d) Immunofluorescence (IF) analysis of LGR5-GFP and PO4-SMAD3 in 914 
murine telogen skin. Nuclei are counterstained with DAPI. (e) Q-RTPCR analysis of Tgfbr1, 915 
Tgfbr2, Tgfb1, Tgfb2, Tgfb3 and Smad7 in LGR5+ve (n=3 biological replicates) and LGR5-ve 916 
cells (n=3 biological replicates) freshly isolated from back skin in the telogen phase. Data are 917 
shown as ratios to the internal Gapdh control with error bars representing s.e.m.. Statistical 918 
significance *p=0.04 (Mann-Whitney U-test, one-tailed test). 919 
 920 
Figure 7. Deletion of Tgfbr1 coupled with BRAF/KRAS activation leads to skin 921 
tumorigenesis. (a) Kaplan-Meier survival curve (left panel) of Lgr5CreER Tgfbr1fl/fl (n=12), 922 
Lgr5CreER BrafV600E (n=14),  Lgr5CreER BrafV600E Tgfbr1fl/+ (n=23) and Lgr5CreER BrafV600E 923 
Tgfbr1fl/fl (n=26) mice (p≤0.0001 by Log-Rank (Mantel-Cox)). Skin tumor free survival curve 924 
(right panel) of Lgr5CreER BrafV600E (n=5), Lgr5CreER BrafV600E Tgfbr1fl/+ (n=10) and Lgr5CreER 925 
BrafV600E Tgfbr1fl/fl (n=19) mice. (b) Kaplan-Meier survival curve of Lgr5CreER KrasG12D (n=9) 926 
and Lgr5CreER KrasG12D Tgfbr1fl/fl (n=14) mice (p<0.0001 by Log-Rank (Mantel-Cox)). (c) 927 
Macroscopic pictures of skin tumours from Lgr5CreER BrafV600E, Lgr5CreER Braf
V600E
 Tgfbr1fl/+, 928 
Lgr5CreER BrafV600E Tgfbr1fl/fl and Lgr5CreER KrasG12D Tgfbr1fl/fl mice.. (d) Representative 929 
staining of KERATIN 1 (K1) and (e) KERATIN 5 (K5) on Lgr5CreER BrafV600E, Lgr5CreER BrafV600E 930 
Tgfbr1fl/+, Lgr5CreER BrafV600E Tgfbr1fl/fl and Lgr5CreER KrasG12D Tgfbr1fl/fl mice. Scale bar, 100 931 
µm. 932 
 933 
Figure 8. Deletion of Tgfbr1 coupled with Tp53 mutation/deletion leads to skin 934 
tumorigenesis. (a) Kaplan-Meier survival curve of Lgr5CreER Tp53R172H/fl (n=31),  Lgr5CreER 935 
Tp53R172/+ Tgfbr1fl/fl (n=10) and Lgr5CreER Tp53fl/+ Tgfbr1fl/fl (n=5) and Lgr5CreER Tp53R172H/fl 936 
Tgfbr1fl/fl (n=11) mice (p≤0.0001 by Log-Rank (Mantel-Cox)). (b) Tumor number of indicated 937 
37 
 
genotypes. (c) Macroscopic picture of a Lgr5CreER Tp53R172H/fl Tgfbr1fl/fl mouse with a skin 938 
tumour. Representative staining of H&E, KERATIN 1 (K1) and KERATIN 5 (K5) is shown. Scale 939 
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